Incidentally, I bought Vascepa last month.  I realized a few things...and concluded it can't be as successful as all these analysts think it will be.  $5 billion is too high a price for it.  But that $5 billion may be the right price for Apabetalone.

Vascepa has to be approved by your insurance company.  I could not get them to pay for it..I did not have the required problems (high triglycerides etc.).  So I paid for it myself.  But on opening the bottle, I immediately realized that Vascepa has a problem.  It looks and feels like the fish oil it is.  

Unless your insurance company pays for it, will people really be willing to pay $10 a day for fish oil, no matter how purified it is?  People won't even pay $30 co pays...for life critical drugs, if the threat perception is not there for healthy people.  I don't know what the NNT data for Vascepa is, but I am dubious about the how diligently the general target population will take it...so the realized NNT may be much higher than what the data will suggest.

Contrast that with Apabetalone.  These are very sick people, who have had a near death experience...and therefore a very high propensity to take their daily Apabetalone pills.  Realized NNT will be very close to those from the trial data.  Secondly, unlike Vascepa, there are few substitutes to Apabetalone.  Third, insurance companies will be keen to pay for reduced MACE events from this very sick population...so their willingness to pay for our drug, may be far higher than Vascepa.

All in all, I think the market is right to take Amarin down some...and it will be constantly surprised to see how well Resverlogix pans out, if we are right in our Phase 3 success expectations.